ImmunityBio, Inc. 8-K

What Happened
On February 23, 2026, ImmunityBio, Inc. (IBRX) filed an 8-K (Item 2.02) to announce a business update and its financial results for the fourth quarter and year ended December 31, 2025, and to report its financial position as of December 31, 2025. The company furnished the full press release as Exhibit 99.1 to the filing.

Key Details

• Press release dated February 23, 2026 announcing Q4 2025 and full-year 2025 results.
• Reporting periods covered: fourth quarter and year ended December 31, 2025; financial position reported as of December 31, 2025.
• Full text of the announcement is furnished as Exhibit 99.1 to the 8-K.
• The filing is submitted under Item 2.02 (Results of Operations and Financial Condition).

Why It Matters
This 8-K is an official earnings/financial-results disclosure that provides investors with the company’s latest quarterly and annual performance and year-end balance-sheet position. Investors should review the furnished press release (Exhibit 99.1) for the detailed figures on revenue, expenses, net income/loss, and cash position, and watch for any follow-up filings (e.g., Form 10-K or earnings presentation) for fuller context and management commentary.